Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy. Amin, A., Milhem, M. M., Long, G. V., Hoimes, C. J., Medina, T., Conry, R., Lao, C. D., Daniels, G. A., Reddy, S. A., Andtbacka, R., Barve, M. A., Shaheen, M. F., Tueting, T., Chisamore, M., Schmidt, E. V., Candia, A., Obiozor, C., Gamelin, E., Janssen, R., Ribas, A. AMER SOC CLINICAL ONCOLOGY. 2019
View details for DOI 10.1200/JCO.2019.37.15_suppl.9555
View details for Web of Science ID 000487345806609